ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016
Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
Alfredo Addeo et al.PubMed ↗Publisher ↗
No numbers read from the abstract.